NCT02440308View on ClinicalTrials.gov

68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Prostate Carcinoma
Interventions
DRUG

68Ga-DOTA-Bombesin

"68Ga-DOTA-Bombesin is a gallium-68-labeled gastrin-releasing peptide receptor (GRPr) antagonist. DOTA is \[4,7,10-Tris-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl\]-acetyl.~68Ga-DOTA-Bombesin is administered intravenously (IV)"

PROCEDURE

Magnetic Resonance Imaging (MRI) scan

PROCEDURE

Positron Emission Tomography (PET) scan

Trial Locations (1)

94305

Stanford University Hospitals and Clinics, Stanford

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Stanford University

OTHER

NCT02440308 - 68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter